|
ERCC4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.15483186849497E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.10629949645613E-10 |
| Normal-vs-Stage2 |
2.027500E-04 |
| Normal-vs-Stage3 |
7.35069782820119E-11 |
| Normal-vs-Stage4 |
1.04030117853426E-11 |
| Stage1-vs-Stage2 |
3.003600E-01 |
| Stage1-vs-Stage3 |
1.384360E-01 |
| Stage1-vs-Stage4 |
1.937890E-03 |
| Stage2-vs-Stage3 |
5.830000E-02 |
| Stage2-vs-Stage4 |
4.142100E-03 |
| Stage3-vs-Stage4 |
1.260630E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.36162217454239E-12 |
| Normal-vs-AfricanAmerican |
1.618860E-04 |
| Normal-vs-Asian |
2.17660000023656E-08 |
| Caucasian-vs-AfricanAmerican |
7.230200E-01 |
| Caucasian-vs-Asian |
4.709400E-01 |
| AfricanAmerican-vs-Asian |
3.859800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.66817687336152E-13 |
| Normal-vs-Female |
6.55909770941321E-11 |
| Male-vs-Female |
5.495800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.28200006166423E-10 |
| Normal-vs-Age(41-60Yrs) |
2.26199947661598E-10 |
| Normal-vs-Age(61-80Yrs) |
3.87220000508393E-09 |
| Normal-vs-Age(81-100Yrs) |
1.323770E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.307000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.197200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.411800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.527400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.885200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.518800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.017900E-04 |
| Classical-VS-Follicular |
5.752800E-01 |
| Classical-VS-Other |
1.568220E-01 |
| Classical-VS-Normal |
1.77340031548567E-10 |
| Tall-VS-Follicular |
1.314010E-02 |
| Tall-VS-Other |
9.551400E-01 |
| Tall-VS-Normal |
4.85169682207243E-11 |
| Follicular-VS-Other |
2.633200E-01 |
| Follicular-VS-Normal |
7.85360000365998E-08 |
| Other-VS-Normal |
8.587100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.61089999514996E-09 |
| Normal-vs-N1 |
4.71790051470578E-10 |
| N0-vs-N1 |
6.271600E-02 |
|
|
